与洛米塔皮德相关的不良事件的现实世界分析:来自FAERS和CVAROD的数据
Xurong Liu1, Zhiwen Zheng2, Qiaoyan Chen3
1Department of Organ Transplantation, The First Affiliated Hospital (Shanghai Changhai Hospital) of Naval Medical University, Shanghai, China.
Medicine
|November 27, 2025
概括
洛米塔皮德有效降低HoFH患者的LDL胆固醇,但存在胃肠道和肝脏不良事件的风险. 密切监测至关重要,特别是在治疗的早期,男性和儿科患者需要个性化策略.
科学领域:
- 药监和药物安全 药监和药物安全
- 心血管疾病治疗方法 治疗方法
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 洛米塔皮德是一种MTP抑制剂,用于同胞性家族性胆固醇高血症 (HoFH).
- 它有效降低LDL胆固醇,但与此相关的安全问题,特别是肝脏和胃肠道不良事件 (AE).
研究的目的:
- 通过自发报告系统对洛米塔皮德安全性进行药监不成比例分析.
- 识别和评估潜在的安全信号,包括新的AE,并评估风险因素.
主要方法:
- 利用美国FDA不良事件报告系统 (FAERS) 和加拿大警不良反应在线数据库 (CVAROD) 的数据.
- 应用了四种统计算法 (ROR,PRR,IC,EBGM) 来分析系统器官类别 (SOC) 和首选术语 (PT) 级别的洛米塔皮德相关报告.
- 采用临床优先评分来根据相关性和影响对AE进行排名.
主要成果:
- 分析了3665个FAERS和80个CVAROD报告,确定了频繁的胃肠道事件 (腹,减肥,恶心) 和肝脏事件 (肝脏酶升高,肝脏肥胖症).
- 观察到代谢并发症,如增加的LDL水平,并确定男性对腹和体重减轻的更高易感性,以及未成年人的腹痛和吐.
- 检测到新的安全信号,包括痛和肠道出血,以前没有在临床试验中报告过. 大多数副作用发生在治疗的第一周内.
结论:
- 洛米塔皮德与显著的胃肠道,肝脏和代谢性副作用有关,男性和儿童群体的风险增加.
- 副作用的早期发作和新信号的出现强调了在洛米塔皮德启动期间需要进行密集监测的必要性.
- 个性化风险减轻策略对于优化Lomitapide在HoFH患者的安全性至关重要.
相关概念视频
01:19Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
01:29Therapeutic Drug Monitoring: Affecting Factors
182
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
182
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
164
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
164
01:16Therapeutic Drug Monitoring: Overview and Classification
275
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
275
01:12Analysis of Population Pharmacokinetic Data
657
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
657
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
135
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
135